EMEA-002568-PIP02-23 - paediatric investigation plan

sonelokimab

Key facts

• Active substance:
  sonelokimab
• Therapeutic area:
  Skin and subcutaneous tissue disorders
• Decision number:
  EMEA-002568-PIP02-23
• PIP number:
  EMEA-002568-PIP02-23
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of hidradenitis suppurativa
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  21/03/2025
• Compliance check done:
  Nē

Decision

EMEA-002568-PIP02-23: EMA decision of 21 March 2025 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sonelokimab

Adopted Reference Number: EMADOC-1700519818-1978526